Risk mitigation strategies to reduce opioid overdoses
Published Date:December 6, 2016
Corporate Authors:Centers for Disease Control and Prevention (U.S.). Office of Public Health Preparedness and Response. Division of Emergency Operations.
Pharmaceutical Services/organization & Administration
Prescription Drug Misuse/prevention & Control
Series:COCA Conference Call
CDC Guideline for Prescribing Opioids for Chronic Pain COCA Call Series ; 6th
Description:CDC guideline for prescribing opioids for chronic pain : risk mitigation strategies : prescription drug monitoring programs (PDMPs), urine drug testing, and naloxone / Deborah Dowell -- Risk mitigation strategies : prescription drug monitoring programs (PDMPs), urine drug testing, and naloxone / Joseph O. Merrill -- Risk mitigation strategies : prescription drug monitoring programs (PDMPs), urine drug testing, and naloxone / Jane C. Ballantyne.
Clinician Outreach and Communication Activity (COCA) conference call Tuesday, December 6, 2016
When prescribing opioids, risk mitigation strategies can be an effective way to reduce abuse and overdose. Strategies described in CDC’s Guideline for Prescribing Opioids for Chronic Pain include reviewing prescription drug monitoring program (PDMP) data, urine drug testing (UDT), and co-prescribing naloxone. During this COCA Call, clinicians will learn about steps they can take when concerning information is discovered through PDMP checks or UDT. Presenters will review how to evaluate factors that increase risk for opioid overdose and how to determine when co-prescribing naloxone would be beneficial. In addition, a case study of a 46-year-old man with chronic low back pain, on high-dose opioid, will be presented to illustrate how PDMP and UDT results and medical evaluation can be used for opioid treatment decision-making.
This is the sixth webinar in a COCA Call series about CDC Guideline for Prescribing Opioids for Chronic Pain.
You May Also Like: